Benzinga | Sep 20, 2021 06:42AM EDT

Verastem Oncology On Sunday Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data Of VS-6766 With Defactinib In Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates And Progression-Free Survival Presented at ESMO 2021

* Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.

* 11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.

* Combination continues to exhibit a favorable tolerability profile.

* Top-line results from the selection portion of Verastem's registration-directed Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.